Lymphatic mapping and sentinel node biopsy: The data unclouded by speculation

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 687-688

  Cochran, Alistair J ^a   Thompson, John F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LETTER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOSCINTIGRAPHY; MELANOMA; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

COLORING AGENTS; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TIME FACTORS;

EID: 44249094872     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.687-a     Document Type: Letter

References (5)

1. Kanzler MH. The current status of evaluation and treatment of high-risk cutaneous melanoma: therapeutic breakthroughs remain elusive. Arch Dermatol. 2007;143(6):785-787.
2. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-399.
3. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317.
4. Morton DL, Cochran AJ, Thompson JF. Sentinel node biopsy for early-stage melanoma [letter]. Ann Surg. 2007;245(5):828-829.
5. Morton DL, Cochran AJ, Thompson JF. Sentinel-node biopsy in melanoma [letter]. N Engl J Med. 2007;356(4):419-420.